中国实用外科杂志2012，Vol.32Issue(11)：950-952,3.
乳腺癌新辅助治疗疗效相关因素分析
Analysis on the factors related with the response of neoadjuvant therapy in primary breast cancer
摘要
Abstract
Objective To assess the effect of neoadjuvant therapy and to investigate the factors related with the response of neoadjuvant therapy in breast cancer patients. Methods We reviewed data of the primary breast cancer patients who had received neoadjuvant therapy with complete MRI data and who had received operation with histopathology evaluation in our center from January, 2009 to August, 2010. The neoadjuvant therapy regimens were based on anthracyclines and taxanes, and trastuzumab was used in most of the HER2 positive patients. The response of neoadjuvant therapy was comprehensively evaluated based on RECIST1.1 and Miller-Payne grading system. Results Among the 105 patients, 12 (11.4%) patients had CR, 68 (64.8%) patients had PR, 24 (22.9%) patients had SD and 1 (1.0% ) patient had PD according to the MRI evaluation. While according to the Miller-Payne grading system, 30 (28.6%) patients had G5, 35 (33.3%) patients had G4,17 (16.2%)patients had G3, 12(11.4%) patients had G2, 11 (10.5% ) patients had Gl. The analysis suggests that the smaller tumor size, fewer positive lymph nodes, and higher histological grade were correlated with pCR statistically. Meanwhile the results of IHC suggested that strong express of HER2, Ki67 and p53 are related to pCR in a statistically significant way (P<0.01), while the express of ER、PR and CK5/6 had no correlation with pCR. Conclusion The effect of new adjuvant therapy can be predicted. The tumor size, lymph node status, histological grade and the IHC results of HER2, Ki67 and p53 were related to the pCR of new adjuvant therapy for primary breast cancer.关键词
乳腺癌/新辅助治疗Key words
breast cancer/new adjuvant therapy分类
医药卫生引用本文复制引用
程岩,徐玲,刘倩,刘荫华..乳腺癌新辅助治疗疗效相关因素分析[J].中国实用外科杂志,2012,32(11):950-952,3.基金项目
首都医学发展基金项目(No:2009-1011) （No:2009-1011）
北京市科技计划项目(No:D090507043409010) （No:D090507043409010）
